The Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 primarily implements eight recommendations of the expert panel review of medicines and medical devices which handed down its stage 1 report, which dealt with regulatory frameworks for medicines and medical devices, in March 2015, and its stage 2 report, which dealt with the regulatory framework for complementary medicines and the advertising of therapeutic goods, in July 2015.